AlphaCentric Advisors LLC Sells 15,789 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

AlphaCentric Advisors LLC reduced its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 87.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,211 shares of the biotechnology company’s stock after selling 15,789 shares during the quarter. AlphaCentric Advisors LLC’s holdings in Sarepta Therapeutics were worth $269,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Manchester Capital Management LLC raised its stake in shares of Sarepta Therapeutics by 86.6% in the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 110 shares during the last quarter. MassMutual Private Wealth & Trust FSB increased its holdings in Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after buying an additional 156 shares in the last quarter. Sunbelt Securities Inc. raised its position in Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after buying an additional 232 shares during the last quarter. Huntington National Bank lifted its position in Sarepta Therapeutics by 150.9% during the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 175 shares during the period. Finally, Newbridge Financial Services Group Inc. purchased a new stake in Sarepta Therapeutics in the fourth quarter worth approximately $36,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT opened at $107.95 on Monday. The firm has a fifty day simple moving average of $119.42 and a two-hundred day simple moving average of $124.60. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The stock has a market capitalization of $10.31 billion, a P/E ratio of 86.36 and a beta of 0.75. Sarepta Therapeutics, Inc. has a 52 week low of $102.15 and a 52 week high of $173.25.

Analysts Set New Price Targets

Several research firms have recently weighed in on SRPT. Cantor Fitzgerald raised Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and increased their price target for the company from $152.00 to $167.00 in a report on Thursday, November 7th. Deutsche Bank Aktiengesellschaft started coverage on Sarepta Therapeutics in a report on Tuesday, February 11th. They issued a “hold” rating and a $136.00 target price on the stock. Evercore ISI cut their target price on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. HC Wainwright reiterated a “sell” rating and issued a $75.00 price target on shares of Sarepta Therapeutics in a research report on Thursday. Finally, Guggenheim boosted their price objective on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $176.77.

Insiders Place Their Bets

In related news, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the sale, the director now directly owns 5,880 shares of the company’s stock, valued at $738,234. This represents a 21.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the firm’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now directly owns 22,840 shares of the company’s stock, valued at approximately $2,851,345.60. The trade was a 31.49 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.